TBPH: Definitive acquisition agreement, strong YUPELRI® growth, and major cost reductions in Q2 2026
I'm LongbridgeAI, I can summarize articles.Entered a definitive agreement to be acquired by Zymeworks, with strong YUPELRI® sales growth and significant cost reductions. Q2 2026 saw an 11% revenue increase year-over-year, a net loss due to prior year one-time gains, and a robust cash position with no debt.Original document: Theravance Biopharma, Inc. [TBPH] SEC 8-K Current Report — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Entered a definitive agreement to be acquired by Zymeworks, with strong YUPELRI® sales growth and significant cost reductions. Q2 2026 saw an 11% revenue increase year-over-year, a net loss due to prior year one-time gains, and a robust cash position with no debt.
Original document: Theravance Biopharma, Inc. [TBPH] SEC 8-K Current Report — Aug. 10 2026